Wellington Management Group LLP Sells 92,568 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

Wellington Management Group LLP trimmed its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 82.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,071 shares of the company's stock after selling 92,568 shares during the period. Wellington Management Group LLP's holdings in Vera Therapeutics were worth $887,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Holocene Advisors LP increased its holdings in Vera Therapeutics by 8.8% during the 3rd quarter. Holocene Advisors LP now owns 1,954,528 shares of the company's stock valued at $86,390,000 after purchasing an additional 158,451 shares during the period. Samlyn Capital LLC increased its stake in shares of Vera Therapeutics by 90.8% during the second quarter. Samlyn Capital LLC now owns 1,231,911 shares of the company's stock valued at $44,571,000 after buying an additional 586,410 shares during the period. First Light Asset Management LLC raised its holdings in shares of Vera Therapeutics by 130.6% during the second quarter. First Light Asset Management LLC now owns 1,005,723 shares of the company's stock valued at $36,387,000 after acquiring an additional 569,590 shares in the last quarter. Logos Global Management LP lifted its stake in Vera Therapeutics by 65.2% in the second quarter. Logos Global Management LP now owns 950,000 shares of the company's stock worth $34,371,000 after acquiring an additional 375,000 shares during the period. Finally, Marshall Wace LLP increased its position in Vera Therapeutics by 9.2% during the 2nd quarter. Marshall Wace LLP now owns 524,578 shares of the company's stock valued at $18,979,000 after purchasing an additional 44,059 shares during the period. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Vera Therapeutics

In other news, Director Beth C. Seidenberg sold 15,000 shares of the firm's stock in a transaction on Monday, October 28th. The stock was sold at an average price of $48.03, for a total value of $720,450.00. Following the transaction, the director now directly owns 131,553 shares in the company, valued at $6,318,490.59. This trade represents a 10.24 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $43.07, for a total value of $753,725.00. Following the completion of the sale, the chief executive officer now directly owns 85,942 shares of the company's stock, valued at $3,701,521.94. The trade was a 16.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 108,125 shares of company stock worth $4,740,588 over the last three months. 21.70% of the stock is currently owned by company insiders.

Vera Therapeutics Stock Up 1.3 %

Shares of VERA stock traded up $0.55 during mid-day trading on Friday, hitting $42.60. The company's stock had a trading volume of 2,228,091 shares, compared to its average volume of 876,029. The stock has a market cap of $2.70 billion, a price-to-earnings ratio of -16.32 and a beta of 1.08. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. Vera Therapeutics, Inc. has a 52-week low of $14.20 and a 52-week high of $51.61. The business has a 50-day moving average price of $45.27 and a 200 day moving average price of $40.47.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.21). Research analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Analysts Set New Price Targets

VERA has been the topic of several research analyst reports. Wells Fargo & Company initiated coverage on shares of Vera Therapeutics in a research report on Thursday, November 21st. They set an "overweight" rating and a $70.00 price target on the stock. Guggenheim increased their target price on Vera Therapeutics from $56.00 to $64.00 and gave the stock a "buy" rating in a research report on Monday, October 28th. Wedbush lifted their price target on Vera Therapeutics from $30.00 to $38.00 and gave the company a "neutral" rating in a research report on Friday, November 8th. JPMorgan Chase & Co. upped their price target on Vera Therapeutics from $72.00 to $75.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $107.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, October 1st. One analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $59.22.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.